Published online before print November 26, 2001, doi: 10.1161/hh0102.102503
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 25, 2001
Revised on November 8, 2001
Accepted on November 9, 2001
Destabilization of AT1 Receptor mRNA by Calreticulin
From Klinik und Poliklinik Innere Medizin III (G.N., F.M., C.M., A.B., T.V., M.B.), Universität des Saarlandes, Homburg, Germany; Institut für Physiologie (A.S.), Universität zu Köln, Germany; and Medizinische Poliklinik (H.V.), Universität Bonn, Germany.
* To whom correspondence should be addressed. E-mail: nickenig{at}med-in.uni-sb.de.
AT1 receptor activation leads to vasoconstriction, blood pressure increase, free radical release, and cell growth. AT1 receptor regulation contributes to the adaptation of the renin angiotensin system to chronic stimulation and serves as explanation for the involvement of the AT1 receptor in the pathogenesis of cardiovascular disease. The molecular mechanisms involved in AT1 receptor regulation are poorly understood. Here, we report that angiotensin II accelerates AT1 receptor mRNA decay in vascular smooth muscle cells. A cognate mRNA region within the 3' untranslated region at bases 2175 to 2195 governs the inducible decay of the AT1 receptor mRNA. Sequential protein purifications led to the discovery of a novel mRNA binding protein, calreticulin, which mediates destabilization of the AT1 receptor mRNA. Angiotensin II--caused phosphorylation of calreticulin enables binding of calreticulin to the AT1 receptor mRNA at bases 2175 to 2195 and propagates calreticulin-induced acceleration of AT1 receptor mRNA decay. Thus, a novel mRNA binding protein, calreticulin, is discovered, which causes AT1 receptor mRNA degradation via binding to a distinct mRNA region in the 3' untranslated region. These findings display a novel mechanism of posttranscriptional mRNA processing.
Key words: angiotensin II • AT1 receptor • mRNA binding protein • mRNA stability • calreticulin
This article has been cited by other articles:
 |
|
 |
|
  M. Backlund, K. Paukku, L. Daviet, R. A. De Boer, E. Valo, S. Hautaniemi, N. Kalkkinen, A. Ehsan, K. K. Kontula, and J. Y. A. Lehtonen Posttranscriptional regulation of angiotensin II type 1 receptor expression by glyceraldehyde 3-phosphate dehydrogenase Nucleic Acids Res., April 1, 2009; 37(7): 2346 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Paukku, N. Kalkkinen, O. Silvennoinen, K. K. Kontula, and J. Y. A. Lehtonen p100 increases AT1R expression through interaction with AT1R 3'-UTR Nucleic Acids Res., August 1, 2008; 36(13): 4474 - 4487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Martin, J. A. Buckenberger, J. Jiang, G. E. Malana, G. J. Nuovo, M. Chotani, D. S. Feldman, T. D. Schmittgen, and T. S. Elton The Human Angiotensin II Type 1 Receptor +1166 A/C Polymorphism Attenuates MicroRNA-155 Binding J. Biol. Chem., August 17, 2007; 282(33): 24262 - 24269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Elton and M. M. Martin Angiotensin II Type 1 Receptor Gene Regulation: Transcriptional and Posttranscriptional Mechanisms Hypertension, May 1, 2007; 49(5): 953 - 961. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yokoyama and K.-i. Hirata New Function of Calreticulin: Calreticulin-Dependent mRNA Destabilization Circ. Res., November 11, 2005; 97(10): 961 - 963. [Full Text] [PDF]
|
|
|
|
|
|
H. Totary-Jain, T. Naveh-Many, Y. Riahi, N. Kaiser, J. Eckel, and S. Sasson Calreticulin Destabilizes Glucose Transporter-1 mRNA in Vascular Endothelial and Smooth Muscle Cells Under High-Glucose Conditions Circ. Res., November 11, 2005; 97(10): 1001 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Khanna Concerted effect of transforming growth factor-{beta}, cyclin inhibitor p21, and c-myc on smooth muscle cell proliferation Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1133 - H1140. [Abstract] [Full Text] [PDF]
|
|